Rebus Biosystems, developer of the patented synthetic aperture optics system, has raised $20 million in a Series B financing round led by Illumina Ventures.
Financing round pulls in $20M for Rebus Biosystems
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.